How India Exports Ceftriaxone to the World

In the United States, ceftriaxone is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. These approvals attest to the drug's established safety and efficacy profiles. The regulatory pathway for ceftriaxone involves demonstrating bioequivalence to the reference listed drug, ensuring consistent therapeutic outcomes. Notably, the presence of 850 active Indian exporters highlights the competitive landscape and the importance of maintaining stringent quality standards to meet FDA requirements.

In the European Union, ceftriaxone is subject to marketing authorization procedures overseen by the European Medicines Agency (EMA). Manufacturers must comply with EU Good Manufacturing Practice (GMP) guidelines to ensure product quality and safety. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates ceftriaxone, requiring adherence to national GMP standards. Compliance with these regulations is essential for market access and maintaining public health standards.

Ceftriaxone is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its critical role in treating a wide range of bacterial infections. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), reflecting its global acceptance and standardized quality benchmarks.

In India, ceftriaxone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for ceftriaxone to ensure affordability; however, the specific ceiling price and its effective date should be verified from the latest NPPA notifications. For exports, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patents for ceftriaxone have expired, allowing for the production and export of generic versions. This has led to increased competition among manufacturers, contributing to the widespread availability and affordability of the drug in global markets.

In May 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of ceftriaxone, which highlights its continued importance in global health. In September 2025, the WHO published the 24th edition of the Model List of Essential Medicines, which includes ceftriaxone, underscoring its critical role in treating bacterial infections. (who.int)

These developments reflect the dynamic nature of the pharmaceutical industry and the ongoing efforts to ensure the availability and affordability of essential medicines like ceftriaxone.

India's pharmaceutical industry, including the production of Ceftriaxone, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the API sector. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact India's pharmaceutical manufacturing capabilities.

In December 2025, Delius Pharmaceuticals received approval from the Central Drugs Standard Control Organisation (CDSCO) to import Ceftriaxone Sodium API directly from China's Guangxi Kelun Pharmaceutical Co., Ltd. This move aims to enhance supply security and reduce reliance on local intermediaries. However, it also underscores the continued dependence on Chinese suppliers for critical antibiotic components.

Our proprietary trade data indicates that the top five Indian exporters of Ceftriaxone account for 31.3% of total exports, with INNOVA CAPTAB LIMITED leading at a 12.7% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could impact global supply chains.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API production and reduce import dependence. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in common antibiotics. While this initiative is a positive step, its impact on reducing supplier concentration in the Ceftriaxone market remains to be seen.

Recent geopolitical tensions have significantly disrupted global shipping routes. In February 2026, the Strait of Hormuz was effectively closed following military conflicts, halting maritime traffic in the Persian Gulf. This closure has severely impacted the transportation of pharmaceuticals from India, leading to delays and increased costs.

Additionally, the Red Sea has experienced heightened threats to commercial shipping due to regional conflicts. Major shipping companies have suspended operations in the area, forcing rerouting via the Cape of Good Hope, which adds significant transit time and costs.

These disruptions have led to increased freight rates and insurance premiums, further straining the pharmaceutical supply chain. The FDA and EMA have issued alerts regarding potential shortages of critical medications, including antibiotics like Ceftriaxone, due to these logistical challenges.

• Diversify API Sourcing: Develop alternative sources for Ceftriaxone APIs and KSMs beyond China to reduce dependency and mitigate supply chain risks.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to boost local manufacturing of critical pharmaceutical ingredients, thereby decreasing reliance on imports.

• Strengthen Supplier Relationships: Establish strategic partnerships with multiple suppliers to ensure a more resilient supply chain and reduce the impact of disruptions affecting a single source.

• Monitor Geopolitical Developments: Implement robust monitoring systems to stay informed about geopolitical events that could impact shipping routes and adjust logistics strategies accordingly.

• Invest in Logistics Flexibility: Develop flexible logistics plans that can adapt to changing shipping conditions, including alternative routes and transportation modes, to ensure continuity in supply chains.

RISK_LEVEL: HIGH